Proskurin Maksim Aleksandrovich

Balykina Y.E., Kolbin A.S., Kurylev A.A., Pavlysh A.V., Proskurin M.A. 1441

Abstract: A pharmacoeconomic evaluation of sunitinib as the firstline metastatic renal-cell carcinoma targeted agent in the Russian healthcare settings was performed in comparison with sorafenib and bevacizumab + interferon. A pharmacoeconomic Markov model was created and used to assess the costs and effectiveness (including mean overall survival in months) of each therapeutic regimen. The evaluation presented also includes a probabilistic multivariate sensitivity analysis. The results show that sunitinibbased treatment is dominant over sorafenib and bevacizumab + interferon, which makes it the most costeffectiveness treatment option.

Balykina Y.E., Kolbin A.S., Kurylev A.A., Proskurin M.A. 1093

Objective of this study was to determine cost-effectiveness of vemurafenib in treatment of inoperable or metastatic melanoma in patients with BRAF V600 mutation from Russian healthcare system perspective and a long-term use. Cost-effectiveness analysis (CEA) has been used and cost-effectiveness ratio (CER) has been calculated. Incremental analysis has been conducted with calculation of incremental cost-effectiveness ratio (ICER) when exceeding the costs and effectiveness of one of the studied regimens as compared to the other one. Cost analysis included calculation of the following direct costs (DC): the cost of the main disease treatment (cutaneous melanoma, CM) – costs of the drug; the cost of laboratory and instrumental methods of investigation as well as hospitalizations and out-patient treatment; the cost required to determine exon 15 BRAF mutation in melanoma; the cost of the drug therapy aimed at management of adverse events (AEs) caused by the drug when treating the main disease. Two medical technologies have been assessed (anti-tumor regimens depending on the chosen method): vemurafenib at a dose of 960 mg twice a day; dacarbazine at a dose of 1000 mg/m2 i/v every 3 weeks. Mathematical modelling underlies this study. As a result it has been demonstrated that the use of vemurafenib strategy in treatment of metastatic melanoma in patients with BRAF V600 mutation had better progression-free survival (PFS) rate throughout the entire modelling horizon. The use of vemurafenib in treatment of metastatic and inoperable melanoma in patients with BRAF V600 mutation is economically advisable taking into account the data on effectiveness (PFS). The use of vemurafenib in patients with BRAF V600 mutation is an absolutely innovative medical technology which currently does not have any alternative. Vemurafenib may be indicated for inclusion in reimbursement lists for treatment of patients with this mutation.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 812

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with complicated skin and soft tissue infections was held. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes more economic sense in terms of cost-efficacy ratio than daptomycin, tigecycline and linezolid. Telavancin use is more advantageous in terms of budget impact analysis as compared to linezolid and daptomycin use: saving up to 32,705,178 rubles from the budget, which enables to treat up to 126 more patients.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 796

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with nosocomial pneumonia was performed in Russia. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes economic sense in terms of cost-efficacy ratio as compared to vancomycin and linezolid. According to the results of analysis of budget impact, for wide use estimated strategy requires additional investment to the extent of 13% when compared with the strategies of the use of vancomycin and linezolid.

Balykina Y.E., Kolbin A.S., Kurylev A.A., Pavlysh A.V., Proskurin M.A. 1441

Abstract: A pharmacoeconomic evaluation of sunitinib as the firstline metastatic renal-cell carcinoma targeted agent in the Russian healthcare settings was performed in comparison with sorafenib and bevacizumab + interferon. A pharmacoeconomic Markov model was created and used to assess the costs and effectiveness (including mean overall survival in months) of each therapeutic regimen. The evaluation presented also includes a probabilistic multivariate sensitivity analysis. The results show that sunitinibbased treatment is dominant over sorafenib and bevacizumab + interferon, which makes it the most costeffectiveness treatment option.

Balykina Y.E., Kolbin A.S., Kurylev A.A., Proskurin M.A. 1093

Objective of this study was to determine cost-effectiveness of vemurafenib in treatment of inoperable or metastatic melanoma in patients with BRAF V600 mutation from Russian healthcare system perspective and a long-term use. Cost-effectiveness analysis (CEA) has been used and cost-effectiveness ratio (CER) has been calculated. Incremental analysis has been conducted with calculation of incremental cost-effectiveness ratio (ICER) when exceeding the costs and effectiveness of one of the studied regimens as compared to the other one. Cost analysis included calculation of the following direct costs (DC): the cost of the main disease treatment (cutaneous melanoma, CM) – costs of the drug; the cost of laboratory and instrumental methods of investigation as well as hospitalizations and out-patient treatment; the cost required to determine exon 15 BRAF mutation in melanoma; the cost of the drug therapy aimed at management of adverse events (AEs) caused by the drug when treating the main disease. Two medical technologies have been assessed (anti-tumor regimens depending on the chosen method): vemurafenib at a dose of 960 mg twice a day; dacarbazine at a dose of 1000 mg/m2 i/v every 3 weeks. Mathematical modelling underlies this study. As a result it has been demonstrated that the use of vemurafenib strategy in treatment of metastatic melanoma in patients with BRAF V600 mutation had better progression-free survival (PFS) rate throughout the entire modelling horizon. The use of vemurafenib in treatment of metastatic and inoperable melanoma in patients with BRAF V600 mutation is economically advisable taking into account the data on effectiveness (PFS). The use of vemurafenib in patients with BRAF V600 mutation is an absolutely innovative medical technology which currently does not have any alternative. Vemurafenib may be indicated for inclusion in reimbursement lists for treatment of patients with this mutation.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 812

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with complicated skin and soft tissue infections was held. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes more economic sense in terms of cost-efficacy ratio than daptomycin, tigecycline and linezolid. Telavancin use is more advantageous in terms of budget impact analysis as compared to linezolid and daptomycin use: saving up to 32,705,178 rubles from the budget, which enables to treat up to 126 more patients.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 796

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with nosocomial pneumonia was performed in Russia. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes economic sense in terms of cost-efficacy ratio as compared to vancomycin and linezolid. According to the results of analysis of budget impact, for wide use estimated strategy requires additional investment to the extent of 13% when compared with the strategies of the use of vancomycin and linezolid.